These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23834829)

  • 1. Pharmacoscintigraphy confirms consistent tamsulosin release from a novel triple-layered tablet.
    Hodges LA; Sime KA; Creech LA; Connolly SM; Barclay ST; Kwon MC; Jeon BJ; Shim SM; Wang HS; Stevens HN; Park JS
    Int J Pharm; 2013 Sep; 454(1):41-6. PubMed ID: 23834829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behaviour and transit of tamsulosin Oral Controlled Absorption System in the gastrointestinal tract.
    Stevens HN; Speakman M
    Curr Med Res Opin; 2006 Dec; 22(12):2323-8. PubMed ID: 17257446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scintigraphic evaluation of the in vivo performance of dry-coated delayed-release tablets in humans.
    Kambayashi A; Sako K; Kondo H
    Eur J Pharm Biopharm; 2020 Jul; 152():116-122. PubMed ID: 32380166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation variation and in vitro-in vivo correlation for a rapidly swellable three-layered tablet of tamsulosin HCl.
    Park JS; Shim JY; Park JS; Lee MJ; Kang JM; Lee SH; Kwon MC; Choi YW; Jeong SH
    Chem Pharm Bull (Tokyo); 2011; 59(5):529-35. PubMed ID: 21532187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz).
    Gao JZh; Hussain MA; Motheram R; Gray DA; Benedek IH; Fiske WD; Doll WJ; Sandefer E; Page RC; Digenis GA
    J Pharm Sci; 2007 Nov; 96(11):2970-7. PubMed ID: 17542016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption, gastrointestinal transit, and tablet erosion of felodipine extended-release (ER) tablets.
    Abrahamsson B; Alpsten M; Hugosson M; Jonsson UE; Sundgren M; Svenheden A; Tölli J
    Pharm Res; 1993 May; 10(5):709-14. PubMed ID: 8321836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of small intestinal transit and colon arrival times of non-disintegrating tablets administered in the fasted state.
    Pišlar M; Brelih H; Mrhar A; Bogataj M
    Eur J Pharm Sci; 2015 Jul; 75():131-41. PubMed ID: 25769525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers.
    Stockis A; Sargentini-Maier ML; Otoul C; Connor A; Wilding I; Wray H
    Clin Ther; 2010 Sep; 32(10):1813-21. PubMed ID: 21194605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo evaluation of the absorption and gastrointestinal transit of avitriptan in fed and fasted subjects using gamma scintigraphy.
    Marathe PH; Sandefer EP; Kollia GE; Greene DS; Barbhaiya RH; Lipper RA; Page RC; Doll WJ; Ryo UY; Digenis GA
    J Pharmacokinet Biopharm; 1998 Feb; 26(1):1-20. PubMed ID: 9773390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and in vivo evaluation of spray dried matrix type controlled-release microparticles of tamsulosin hydrochloride for orally disintegrating tablet.
    Park CW; Kim JY; Rhee YS; Oh TO; Ha JM; Park ES
    Drug Dev Ind Pharm; 2012 Oct; 38(10):1179-87. PubMed ID: 22200122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacoscintigraphic study of three time-delayed capsule formulations in healthy male volunteers.
    McConville JT; Hodges LA; Jones T; Band JP; O'Mahony B; Lindsay B; Ross AC; Florence AJ; Stanley AJ; Humphrey MJ; Wilson CG; Stevens HN
    J Pharm Sci; 2009 Nov; 98(11):4251-63. PubMed ID: 19387976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal transit of model mini-tablet controlled release oral dosage forms in fasted human volunteers.
    Podczeck F; Course N; Newton JM; Short MB
    J Pharm Pharmacol; 2007 Jul; 59(7):941-5. PubMed ID: 17637188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib?
    Wilson CG; O'Mahony B; Connolly SM; Cantarini MV; Farmer MR; Dickinson PA; Smith RP; Swaisland HC
    Int J Pharm; 2009 Jul; 376(1-2):7-12. PubMed ID: 19497691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo evaluation of guargum-based colon-targeted oral drug delivery systems of celecoxib in human volunteers.
    Krishnaiah YS; Satyanarayana V; Dinesh Kumar B; Karthikeyan RS; Bhaskar P
    Eur J Drug Metab Pharmacokinet; 2002; 27(4):273-80. PubMed ID: 12587957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing gastrointestinal motility and disintegration profiles of magnetic tablets by a novel magnetic imaging device and gamma scintigraphy.
    Goodman K; Hodges LA; Band J; Stevens HN; Weitschies W; Wilson CG
    Eur J Pharm Biopharm; 2010 Jan; 74(1):84-92. PubMed ID: 19602377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gamma scintigraphic evaluation of film-coated tablets intended for colonic or biphasic release.
    Ofori-Kwakye K; Fell JT; Sharma HL; Smith AM
    Int J Pharm; 2004 Feb; 270(1-2):307-13. PubMed ID: 14726145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers.
    Brunner M; Lackner E; Exler PS; Fluiter HC; Kletter K; Tschurlovits M; Dudczak R; Eichler HG; Müller M
    Aliment Pharmacol Ther; 2006 Jan; 23(1):137-44. PubMed ID: 16393291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meal-induced acceleration of tablet transit through the human small intestine.
    Fadda HM; McConnell EL; Short MD; Basit AW
    Pharm Res; 2009 Feb; 26(2):356-60. PubMed ID: 18982248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.